股市必读：国际医学（000516）2月5日董秘有最新回复

Core Viewpoint - The company International Medicine (000516) is facing challenges related to its stock performance and ongoing capital increase plans, amid concerns over major shareholder actions and industry policy changes [1][2][3] Group 1: Stock Performance - As of February 5, 2026, International Medicine's stock closed at 4.95 yuan, down 0.4%, with a turnover rate of 1.41%, trading volume of 311,800 shares, and a transaction value of 155 million yuan [1] - On the same day, there was a net outflow of 14.1651 million yuan from major funds, indicating a short-term reduction in holdings by institutional investors [3] Group 2: Capital Increase and Shareholder Concerns - The company is currently in the process of a non-public offering, but the specific issuance targets have not yet been determined, leading to investor concerns about potential shareholder dilution and stock price impacts [2] - Major shareholder Century Xinyuan has pledged 82.07% of its shares as of mid-January 2026, raising questions about control and financial stability, although the company asserts that the risk is manageable [2] Group 3: Operational Strategies - In response to ongoing healthcare policy reforms, the company is focusing on enhancing operational efficiency and cost control, particularly in specialized medical fields such as neurology, cardiology, and oncology [2][3] - The company is also exploring differentiated business strategies in areas like aesthetic medicine, rehabilitation, and elder care to build competitive advantages and improve service value [2]